Breast cancer immunotherapy: Current status and future prospects

Immunology and Cell Biology

Volumn 74, Issue 5, 1996, Pages 457-464

  Apostolopoulos, Vasso ^a   McKenzie, Ian F C ^a   Pietersz, Geoffrey A ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Breast cancer; Cytokines; Mannan; MUC1; Mucin 1; Vaccine

Indexed keywords

CANCER VACCINE; MANNAN;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOGENICITY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL;

ANIMALIA;

EID: 0029801151     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1996.76     Document Type: Article

References (41)

1. van der Bruggen P, Traversari P, Chomez C et al. A gene encoding an antigen recognised by CTL on human melanoma. Science 1991; 254: 1643-6.
2. Kawakami Y, Eliyaha S, Delgado CH et al. Cloning of the gene coding for a shared human-melanoma antigen recognised by autologous T-cells infiltrating into tumour. Proc. Natl Acad. Sci. USA 1994; 91: 3515-19.
3. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human CTL specific for peptides derived from the Her-2/neu protooncogene protein. Cancer Res. 1994; 54: 1071-6.
4. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumour antigen. Proc. Natl Acad. Sd. USA 1995; 92: 11 993-7.
5. Gendler SJ, Papadimitriou JT, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. Biol. Chem. 1989; 263: 12 820-3.
6. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu. Rev. Physiol. 1995; 57: 607-34.
7. Hilkens J, Lightenberg MJL, Vos HL, Litvinov SV. Cell membrane-associated mucins and their adhesion-modulating property. TIBS 1992; 17: 359-63.
8. Itzkowitz SH, Yuan M, Montgomery CK et al. Expression of Tn, sialosyl-Tn and T antigens in human colon cancer. Cancer Res. 1989; 49: 197-204.
9. Xing PX, Tjandra JJ, Stacker SA et al. Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol. Cell Biol. 1989; 67: 183-95.
10. Xing PX, Reynolds K, Tjandra JJ, Tang XL, McKenzie IFC. Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies. Cancer Res. 1990; 50: 89-96.
11. Xing PX, Prenzoska J, Quelch K, McKenzie IFC. Second generation anti-MUC1 peptide monoclonal antibodies. Cancer Res. 1992; 52: 2310-17.
12. Xing PX, Prenzoska J, McKenzie IFC. Second generation mAbs to intestinal MUC2 peptide reactive with colon cancer. J. Natl Cancer Inst. 1992; 84: 699-703.
13. Apostolopoulos V, Xing PX, Trapani JA, McKenzie IFC. Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein. Br. J. Cancer 1993; 67: 713-20.
14. Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific MHC-unrestricted recognition of tumour-associated mucins by human CTL. Proc. Natl Acad. Sci. USA, 1989; 86: 7159-63.
15. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. CTL from ovarian malignant tumours can recognise polymorphic epithelial mucin core peptides. J. Immunol. 1993; 151: 3693-703.
16. Jerome KR, Domenech N, Finn OJ. Tumour-specific CTL clones from patients with breast and pancreatic adenocarcinoma recognise EBV-immortalised B cells transfected with polymorphic epithelial mucin cDNA. J. Immunol. 1993; 151: 1654-62.
17. + CTL protect human peripheral blood leucocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism. J. Immunol. 1994; 153: 4826-31.
18. Takahashi T, Mukiguchi Y, Hinoda Y et al. Expression of MUC1 on myeloma cells and induction of HLA Unrestricted CTL against MUC1 from a multiple myeloma patient. J. Immunol. 1994; 153: 2102-9.
19. Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat of the epithelial tumour antigen MUC1. J. Immunol. 1995; 155: 4766-74.
20. Rughetti A, Turchi V, Ghetti CA et al. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res. 1993; 53: 2457-9.
21. Kotera Y, Fontenont JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res. 1994; 54: 2856-60.
22. Hinoda Y, Nakagawa N, Nakamura H et al. Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis. Immunol. Lett. 1993; 35: 163-8.
23. Apostolopoulos V, Loveland BE, Pietersz GA, McKenzie IFC. CTL in mice immunised with human Mucin 1 are MHC-restricted. J. Immunol. 1995; 155: 5089-94.
24. Hird V, Maraveyas A, Snook D et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer 1993; 68: 403-10.
25. Hareuveni M, Gautier C, Kieny MP, Wreschner D, Chambon P, Lathe R. Vaccination against tumour cells expressing breast cancer epithelial tumour antigen. Proc. Natl Acad. Sci. USA 1990; 87: 9498-502.
26. Acres B, Hareuveni M, Balloul JM, Kieny MP. VV-MUC1 immunisation of mice-immune response and protection against the growth of murine tumours bearing the MUC1 antigen. J. Immunother. 1993; 14: 136-43.
27. Acres B, Dott K, Stefani L, Kieny MP. Directed cytokine expression in tumour cells in vivo using recombinant vaccinia virus. Theor. Immunol. 1994; 1: 17-23.
28. Lalani E-N, Berdichevsky F, Boshell M et al. Expression of the gene coding for a human mucin in mouse mammary tumour cells can affect their tumourigenicity. J. Biol. Chem. 1991; 266: 15420-6.
29. Apostolopoulos V, Xing PX, McKenzie IFC, Murine immune response to cells transfected with human MUC1: Immunisation with cellular and synthetic antigens. Cancer Res. 1994; 54: 5186-93.
30. Graham RA, Stewart LS, Beverley P, Papadimitriou JT. MUC1-based immunogens for tumour therapy: development of murine model systems. Tumour Targeting 1995; 1: 211-21.
31. Ding L, Lalani EN, Reddish M et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 gene: Effect of immunisation on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. 1993; 36: 9-17.
32. Papadimitriou JT, Stewart L, Burchell J, Beverley P. The polymorphic epithelial mucin as a target for immunotherapy. Ann. NY Acad. Sci. 1994; 690: 69-79.
33. Liu X, Scjbal J, Kotovych G et al. Structurally defined synthetic cancer vaccines: Analysis of structure, glycosylation and recognition of cancer associated mucin. MUC-I derived peptides. Glycoconj. J. 1995; 12: 607-17.
34. Xing PX, Michaels M, Apostolopoulos V, Prenzoska J, Bishop J, McKenzie IFC. Phase I study of synthetic MUC1 peptides in cancer. Int. J. Oncol. 1995; 6: 1283-9.
35. Apostolopoulos V, Pietersz GA, McKenzie IFC. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1995 (in press).
36. 2 immune responses. Proc. Natl Acad Sci USA 1995; 92: 10128-32.
37. Parish CR. Immune response to chemically modified flagellin. I. Induction of antibody tolerance to flagellin by acetoacetylated derivatives of the protein. J. Exp. Med. 1971; 134: 1-20.
38. Rhodes J, Chen H, Hall Sr et al. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature 1995; 377: 71-5.
39. Soltysik S, Wu J, Recchia J et al. Structure/function studies of QS-21 adjuvant: assessment of triterpcne aldehyde and glucoronic acid roles in adjuvant function. Vaccine 1995; 15: 1403-10.
40. Gao X, Rhodes J. An essential role for constitutive Schiff base-forming ligands in antigen presentation to murine T cell clones. J. Immunol. 1990; 144: 2883-90.
41. Zheng B, Brett SJ, Tite JP, Lifely R, Brodie AB, Rhodes J. Galactose oxidation in the design of immunogenic vaccines. Science 1992; 256: 1560-63.